Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Update

Palisade Bio, Inc. (NASDAQ:PALIGet Rating) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 481,800 shares, a drop of 59.5% from the April 30th total of 1,190,000 shares. Currently, 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is presently 0.3 days.

Shares of Palisade Bio stock traded up $0.07 on Friday, hitting $0.59. 2,061 shares of the company’s stock traded hands, compared to its average volume of 1,459,699. The company has a fifty day moving average of $0.80 and a two-hundred day moving average of $1.25. Palisade Bio has a one year low of $0.40 and a one year high of $4.57. The company has a market capitalization of $12.91 million, a price-to-earnings ratio of -0.16 and a beta of 1.63.

Palisade Bio (NASDAQ:PALIGet Rating) last issued its quarterly earnings results on Friday, May 13th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. As a group, analysts expect that Palisade Bio will post -0.57 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Palisade Bio by 11.5% in the first quarter. Vanguard Group Inc. now owns 271,604 shares of the company’s stock worth $288,000 after buying an additional 28,014 shares in the last quarter. Altium Capital Management LP bought a new stake in shares of Palisade Bio in the fourth quarter worth about $434,000. Geode Capital Management LLC grew its stake in shares of Palisade Bio by 21.6% in the fourth quarter. Geode Capital Management LLC now owns 208,563 shares of the company’s stock worth $271,000 after purchasing an additional 37,033 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Palisade Bio in the fourth quarter worth about $105,000. Finally, Northern Trust Corp bought a new stake in shares of Palisade Bio in the fourth quarter worth about $30,000. 7.88% of the stock is owned by institutional investors and hedge funds.

Several analysts have issued reports on the company. LADENBURG THALM/SH SH assumed coverage on Palisade Bio in a report on Wednesday, February 2nd. They set a “buy” rating and a $5.00 price objective on the stock. Zacks Investment Research upgraded Palisade Bio from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Thursday.

Palisade Bio Company Profile (Get Rating)

Palisade Bio, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery.

See Also

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with's FREE daily email newsletter.